NRx Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

NRx Pharmaceuticals ha registrato una crescita degli utili a un tasso annuo medio di 8%, mentre il settore Pharmaceuticals ha visto gli utili diminuire a un tasso annuo di 0.2%.

Informazioni chiave

8.0%

Tasso di crescita degli utili

25.0%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	6.0%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	n/a
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come NRx Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqCM:NRXP Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	-25	13	10
31 Mar 24	-26	13	11
31 Dec 23	-30	14	13
30 Sep 23	-36	18	15
30 Jun 23	-39	20	16
31 Mar 23	-37	23	15
31 Dec 22	-40	27	17
30 Sep 22	-60	68	19
30 Jun 22	-88	77	21
31 Mar 22	-81	83	23
31 Dec 21	-93	75	20
30 Sep 21	-108	35	18
30 Jun 21	-76	25	16
31 Mar 21	-76	13	13
31 Dec 20	-52	11	11
30 Sep 20	-8	6	7

Guadagni di qualità: NRXP al momento non è redditizia.

Margine di profitto in crescita: NRXP al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: NRXP non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 8% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di NRXP nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: NRXP non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 13% ).

Rendimento del capitale proprio

ROE elevato: Le passività di NRXP superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

NRx Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

NRx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024

NRx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024

NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Recent updates

NRx Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024

NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer

NRx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024

NRx Pharmaceuticals Receives Letter from the Listing Qualifications Staff of the Nasdaq Regarding Market Value of Listed Securities

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine)

NRx Pharmaceuticals, Inc. to Proceed with Two New Drug Applications in 2024

NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors

NRx Pharmaceuticals, Inc. Presents Landmark Trial of Nrx-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: Nrx-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression

NRx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.0031 million.

NRx Pharmaceuticals Demonstrates Compliance with the Nasdaq Bid Price Requirement in Listing Rule 5550(a)(2)

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics

NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024

NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

New major risk - Share price stability

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

Panel Grants NRx Pharmaceuticals Request for an Exception to Nasdaq Listing Rules Until April 16, 2024, to Demonstrate Compliance with the Rule

NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

Price target increased by 7.1% to US$3.75

NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

New major risk - Financial position

NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

NRx Pharmaceuticals Receives Formal Notice from the Listing Qualifications Staff of Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101

NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain

NRx Pharmaceuticals, Inc. announced that it expects to receive $1.2 million in funding

Co-Founder recently bought US$64k worth of stock

New major risk - Share price stability

NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

NRx Pharmaceuticals Receives Written Notification from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.285501 million.

Price target increased by 7.7% to US$3.50

NRx Pharmaceuticals, Inc. Reports Minutes of U.S. Food and Drug Administration Meeting on Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

CEO & Director recently bought US$59k worth of stock

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Independent Director recently bought US$515k worth of stock

High number of new and inexperienced directors

NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

NRx Pharmaceuticals, Inc. Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito